⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Official Title: AN OPEN LABEL, SINGLE ARM PHASE 1B STUDY OF AVELUMAB PLUS AXITINIB AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

Study ID: NCT03289533

Study Description

Brief Summary: To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC

Detailed Description:

Eligibility

Minimum Age: 20 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Aichi Cancer Center Hospital, Nagoya, Aichi, Japan

Iizuka Hospital, Iizuka, Fukuoka, Japan

Kindai University Hospital, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan

National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

Kyorin University Hospital, Department of Medical Oncology, Mitaka-shi, Tokyo, Japan

Japanese Red Cross Musashino Hospital, Musashino, Tokyo, Japan

National Hospital Organization Kyushu Medical Center, Fukuoka, , Japan

Contact Details

Name: Pfizer CT.gov Call Center

Affiliation: Pfizer

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: